蜂胶佐剂对异育银鲫嗜水气单胞菌灭活疫苗的免疫增强试验

本文就蜂胶佐剂对鱼类细菌性疫苗的免疫增强作用进行了首次评价。试验以异育银鲫嗜水气单胞菌灭活疫苗为对象,比较了蜂胶佐剂、铝胶佐剂和无佐剂三种疫苗对银鲫的免疫效果。经抗体监测表明,免疫接种后第2周,蜂胶佐剂组银鲫已检测到血清抗体,随后抗体效价迅速上升,第4周达到峰值2^5：铝胶佐剂组和无佐剂组第3周检测到抗体．铝胶佐剂组第5周达到峰值2^5,无佐剂组第4周达到峰值2^4。银鲫免疫后第5周进行攻毒保护试验,发现蜂胶佐剂组、铝胶佐剂组和无佐剂组的免疫保护率分别为77．3％．65．0％和56．3％。试验结果表明,蜂胶佐剂能有效增强异育银鲫细菌性灭活疫苗的免疫保护力。     

山莨菪碱提高嗜水气单胞菌灭活疫苗浸泡免疫鲫的效果

为研究山莨菪碱作为佐剂在细菌灭活疫苗浸泡免疫中的作用,将山莨菪碱和嗜水气单胞菌全菌灭活疫苗联合浸泡免疫异育银鲫,首次浸泡免疫7d后加强免疫1次.通过实时荧光定量PCR检测第2、4、7、11、14和21天脾脏中IgM、IL-1β、C3、C-凝集素以及溶菌酶的mRNA表达量,并在第21天进行同源菌株活菌攻击实验.结果显示,山莨菪碱组第4天IgM和IL-1 β的表达量达到最高值,分别为28.3和332.7;而无佐剂疫苗组第11天IgM和IL-1β达到最高值,分别为56.1和791.8.山莨菪碱组的补体C3、C-凝集素以及溶菌酶的表达量都显著高于无佐剂组和对照组,且表达持续时间长.活菌攻击实验表明山莨菪碱组的相对免疫保护率可达80.0％,显著高于无佐剂组的56.0％.结果表明,山莨菪碱与嗜水气单胞菌灭活疫苗共同浸泡免疫银鲫,可以增强脾脏中IgM、IL-1β、C3、C-凝集素以及溶菌酶基因表达,提高银鲫相对免疫保护率.     

二种佐剂对哈氏弧菌OMPC-溶藻弧菌LPS偶联疫苗的增效作用

制备哈氏弧菌SpGY020601外膜蛋白复合物(OMPC)和溶藻弧菌EpGS021001脂多糖(LPS)偶联疫苗,设置偶联疫苗组、偶联疫苗 ISA763佐剂组、偶联疫苗 β-葡聚糖佐剂(DEAE)组以及生理盐水对照组,并以相同程序免疫卵型鲳鲹。溶菌酶活性检测、微量凝集反应试验结果显示:各疫苗组血清中的溶菌酶含量无显著差异(P>0.05),但均远高于生理盐水对照组(P<0.05);ISA763佐剂组抗哈氏弧菌SpGY020601抗体滴度较其他组出现的早,抗溶藻弧菌EpGS021001抗体滴度较其他组持续时间长;β-葡聚糖佐剂组次之,其次是无佐剂组,对照组始终未检测到抗体。各组分为腹腔注射攻毒与浸泡攻毒,对EpGS021001的攻击,ISA763佐剂组相对保护率分别为90%和70%,高于β-葡聚糖佐剂组的85%和55%,以及无佐剂组的80%和55%;对SpGY020601的攻击,ISA763佐剂组相对保护率分别为95%和80%,高于或相当于β-葡聚糖佐剂组的95%和75%,以及无佐剂组的90%和75%。     

一种佐剂新材料在嗜水气单胞菌灭活疫苗浸泡免疫鲫中的应用效果

为研究蓖麻油聚乙二醇单酯葡萄糖苷(CPMG)在细菌灭活疫苗浸泡免疫中的佐剂作用,将CPMG和嗜水气单胞菌灭活疫苗联合施用,二次浸泡免疫异育银鲫后饲养在室内玻璃缸中,用实时荧光定量PCR(RT-PCR)检测加强免疫后2、4、7、11、14和21 d脾脏中Ig M、IL-1β、C3、C-凝集素和溶菌酶的m RNA表达量,首次免疫30 d后用同源菌株活菌攻击实验鱼;同时,用含CPMG、山莨菪碱复合佐剂的灭活疫苗浸泡免疫异育银鲫一次后饲养在池塘网箱中,定期抽取血液检测血清抗体效价并用同源菌株人工感染实验鱼。结果显示,CPMG佐剂组和无佐剂组的5个免疫相关基因的相对表达量显著高于对照组,CPMG组Ig M基因较无佐剂组更早表达,补体C3、C-凝集素以及溶菌酶的基因表达量更高或表达持续时间更长。血清抗体效价在免疫后2周达到160,6周达到峰值640,12周降低为40。室内玻璃缸中二次免疫30 d后,CPMG组的平均相对保护率达到70.6%,复合佐剂组达到88.2%,均显著高于无佐剂组的56.0%。池塘网箱中一次浸泡免疫30、60和120 d后,平均相对保护率分别为54.6%、44.0%和12.5%。研究表明,CPMG与嗜水气单胞菌灭活疫苗共同浸泡免疫异育银鲫,增强了脾脏中Ig M、IL-1β、C3、C-凝集素以及溶菌酶基因表达,提高了异育银鲫抗嗜水气单胞菌感染的能力。     

嗜水气单胞菌灭活疫苗对虹鳟免疫力和抗病力的影响

为研究嗜水气单胞菌(Aeromonas hydrophila)灭活疫苗对虹鳟(Oncorhynchus mykiss)(250 g±12 g)免疫力和抗病力的影响,给试验鱼腹腔注射0.2 mL的灭活嗜水气单胞菌悬液(1.0×108cfu/mL)。分别在注射前(0 d)和注射后7、14、21、28、35、42 d取样,测定血液白细胞吞噬活性、血清溶菌酶(LZM)活力、补体C3含量以及头肾和脾脏中IgM、IgT基因表达情况。结果表明:注射嗜水气单胞菌疫苗能显著提高白细胞吞噬率(PP)和吞噬指数(PI)、LZM活力和补体C3含量,注射后21 d达峰值,PI、LZM和补体C3在42 d仍显著高于对照组。免疫后21 d头肾和脾脏中IgM基因上调表达,35 d达峰值(分别上升24倍和26倍),42 d下降但仍极显著高于对照组。头肾和脾脏中IgT的上调表达比IgM弱得多,头肾35 d达峰值(上升6.2倍),脾脏28 d达峰值(上升6.1倍)。免疫42 d后嗜水气单胞菌攻毒结果表明,嗜水气单胞菌灭活疫苗对虹鳟有较高的免疫保护作用,免疫保护率达到71.43%。     

不同佐剂对大鲵嗜水气单胞菌灭活疫苗的免疫效果

为了探究添加蜂胶佐剂、弗氏佐剂和铝胶佐剂后对大鲵（Andrias davidianus）嗜水气单胞菌（Aeromonas hydrophila）灭活疫苗的免疫效果,取已制备好的大鲵嗜水气单胞菌灭活疫苗,分别加入3种佐剂,充分混匀后制备成含菌量为1×108 CFU/mL的佐剂疫苗,通过腹腔注射免疫健康大鲵(平均体长40 cm、平均体质量85 g）,每尾1 mL,并设不加佐剂组和对照组;分别于免疫后第1、4、7、14、21、28、35天尾静脉采血,利用凝集反应检测血清抗体效价,于免疫后第35天进行攻毒感染试验。结果表明,与对照组相比,蜂胶佐剂组抗体效价于免疫后第1～14天呈上升趋势,第21天达最高,为1: 469.33,弗氏佐剂组于免疫后第1～28天呈上升趋势,第35天达到最大值,为1: 448.00,随后呈下降趋势;铝胶佐剂组抗体效价于免疫后第1～21天呈上升趋势,第28天达到最大值,为1: 362.67,不加佐剂组于免疫后第21天达最高,为1: 384.00,随后呈下降趋势,而对照组基本稳定在1:4.00。攻毒感染试验表明,蜂胶佐剂组、弗氏佐剂组、铝胶佐剂组和不加佐剂组的死亡率为10%、20%、25%和35%,相对免疫保护率分别为88.9%、77.8%、72.2%和61.1%,对照组大鲵死亡率为90%;3种佐剂疫苗均有较好的免疫保护效果,其中以蜂胶佐剂疫苗效果最佳。     

鲖爱德华菌口服疫苗对斑点鲖的免疫效果

为评价鲖爱德华菌口服微球疫苗对斑点鲖的免疫效果,实验以天然高分子聚合物海藻酸钠和鲖爱德华菌灭活疫苗为材料,制备鲖爱德华菌口服微球疫苗。将实验动物随机分为鲖爱德华菌微球疫苗组、鲖爱德华菌灭活疫苗组、空微球组和对照组,以拌料口服方式进行免疫,通过检测血清中溶菌酶活力、总超氧化物歧化酶(T-SOD)活力、补体替代途径(ACH50)活性等非特异性免疫指标,抗体效价以及相对免疫保护率评价疫苗免疫效果,采用荧光定量PCR检测口服疫苗对斑点鲖免疫相关基因表达量的影响。结果显示,鲖爱德华菌口服微球疫苗能够较长时间增强斑点鲖非特异性免疫功能;血清凝集效价于第5周达到峰值,为1∶16,免疫后第7周仍可检测到特异性抗体;口服鲖爱德华菌微球疫苗的斑点鲖获得的抗鲖爱德华菌相对免疫保护率为60.7%,远高于灭活疫苗组(14.3%)及空微球组(10.7%);荧光定量分析结果显示,攻毒后48 h相比攻毒前各免疫基因表达量均有上调,鲖爱德华菌微球疫苗对受免鱼肾脏、脾脏中免疫基因的表达影响尤为明显。结果表明,鲖爱德华菌口服微球疫苗能增强斑点鲖非特异性免疫功能,对鲖爱德华菌病起到一定的预防作用。     

杀鲑气单胞菌灭活疫苗的制备及其在大菱鲆体内的免疫效果

为了预防大菱鲆疥疮病,本研究将杀鲑气单胞菌菌株HHSM1905经甲醛灭活制备成灭活疫苗,通过腹腔注射途径免疫健康大菱鲆;对免疫后大菱鲆血清抗体效价、血清溶菌酶(LZM)活性、酸性磷酸酶(ACP)活性及疫苗保护率进行测定;以β-actin为内参,对免疫相关基因(IL-1β、TLR-5、MHCⅠ、MHCⅡ-α、CD4)表达情况进行定量PCR分析。结果显示,在免疫后2周时,疫苗组血清抗体效价显著高于对照组并达到最大值;疫苗组LZM活性在免疫2周时达到峰值,4周时仍与对照组保持显著差异;疫苗组ACP活性在免疫后的2周达到峰值,与对照组差异显著;灭活疫苗相对保护率(RPS)为72.72%。免疫组与对照组相比,IL-1β、TLR-5、MHCⅠ、MHCⅡ-α、CD4的表达量均呈上调趋势,与对照组差异显著。本研究成功制备了大菱鲆用杀鲑气单胞菌灭活疫苗,其对大菱鲆疥疮病能够起到一定的预防作用,可为大菱鲆养殖过程中疾病预防提供新方法。     

鳗弧菌O1/O2二价灭活疫苗免疫大菱鲆的抗体持续期和免疫保护期

本研究分析了鳗弧菌(Vibrio anguillarum)O1/O2血清型二价灭活疫苗免疫大菱鲆后的抗体持续期和免疫保护期。以鳗弧菌O1血清型VAM003株和O2血清型VAM007株为抗原制备了福尔马林灭活二价疫苗,将疫苗按照三种剂量(10~7 cells/尾、10~8 cells/尾、10~9 cells/尾)以腹腔注射途径免疫大菱鲆,在免疫后3 d、7 d、14 d、30 d、60 d、90 d、120 d、150 d,用血清凝集实验检测了免疫鱼血清的VAM003和VAM007抗体效价,用攻毒实验检测了疫苗的免疫保护率(RPS)。结果显示,在免疫后7 d三个剂量组的大菱鲆均产生了特异抗体,并获得27%～60%的RPS。三个剂量组大菱鲆的O1血清型抗体持续期分别90 d (10~7 cells/尾组)、150 d (10~8 cells/尾组)、150 d (10~9cells/尾组),而三个剂量组大菱鲆的O2血清型抗体持续期均150 d。三个剂量组的大菱鲆获得的免疫保护持续期均150 d;以RPS75%为有效免疫保护,各剂量组大菱鲆抵抗O1血清型病原感染的有效免疫保护期为:14～120d(10~7 cells组)、14～120 d (10~8 cells/尾)、14～150 d (10~9 cells/尾),抵抗O2血清型病原感染的有效免疫保护期为:14～60 d (10~7 cells组)、14～120 d (10~8 cells/尾)、14～120 d (10~9 cells/尾)。研究结果表明鳗弧菌二价灭活疫苗可为大菱鲆提供有效而稳定的免疫保护,获得的抗体持续期和免疫保护期为该疫苗的临床中试研究提供了基础。     

传染性造血器官坏死病灭活疫苗的制备及免疫保护效果

为了研发用于预防传染性造血器官坏死病(infectious hematopoietic necrosis,IHN)灭活疫苗,实验以不同感染复数(multiplicity of infection,MOI)在胖头鱥上皮细胞(Epithelioma papulosum cyprinid,EPC)上对传染性造血器官坏死病毒(infectious hematopoietic necrosis virus,IHNV)进行连续传代培养,通过测定各代病毒滴度,结合病毒收获时间确定最佳增殖方案;采用不同浓度的β-丙内酯(β-propanolactone,BPL)在24℃下灭活,经安全性实验验证后确定最佳灭活条件。以不同剂量腹腔注射免疫虹鳟,以磷酸盐缓冲溶液(PBS)为阴性对照组,通过检测攻毒后相对免疫保护率(relative percent survival,RPS)、免疫相关因子表达量及血清中和抗体效价来分析该疫苗的保护效果。结果显示,最佳增殖方案为以MOI为0.000 1接种,15℃培养3 d;最佳灭活条件为以终浓度3.0 mmol/L的BPL将IHNV在24℃下灭活24 h;以最佳免疫剂量10μL/尾腹腔注射免疫虹鳟,免疫后7、21、45和60 d的相对免疫保护率分别为91.37%、84.28%、84.15%和47.5%,免疫后60 d时RPS显著低于其他时间点免疫组;免疫相关基因的实时荧光定量PCR(realtime quantitative PCR,RT-qPCR)结果显示,与阴性对照组相比,Mx-1和IFN-γ表达量在免疫后7、15和30 d脾脏和头肾中均显著上调,在第7天时达到最大值(5倍);CD4和IgM表达量在免疫后15 d脾脏和头肾中均显著上调;在免疫后第30、45和60天虹鳟血清IHNV中和抗体效价依次为67.25、43.40和29.78,呈下降趋势且各组间差异显著。研究表明,该灭活疫苗可诱导虹鳟产生特异性免疫和非特异性免疫反应,对虹鳟具有显著的免疫保护作用。本研究为IHNV灭活疫苗研发提供参考。     

基因工程疫苗概述

疫苗在动物疫病的防控中起着巨大作用,但传统疫苗(灭活苗、弱毒苗)已不能跟上当前畜牧业发展的的步伐。基因工程疫苗作为分子生物技术发展的新兴产物克服了传统疫苗的生产成本高、免疫途径局限、安全性较低等缺点,成为动物疫苗发展的新方向。文章概述了几种常用基因工程疫苗的特点及研究进展,为进一步研究提供文献参考。     

草鱼“四联”疫苗在草鱼池塘养殖生产中的应用

利用4口池塘,每公顷放养75～100g/尾的草鱼种31 612尾～36 486尾。其中2口池草鱼种放养时接种草鱼"四联"疫苗,另2口池设为对照。经6个月的饲养试验,结果表明:接种疫苗的试验池草鱼与未接种疫苗的对照池相比,发病率比对照池低10.7%,成活率与平均产量比对照池分别提高12.8%和20.8%。试验初步证明,接种草鱼四联疫苗能有效地增强草鱼对"四病"的抵御能力,提高草鱼养殖成活率,是有效防治草鱼"四病"的有效措施之一。     

Rainbow trout (Oncorhynchus mykiss) immune response towards a recombinant vaccine targeting the parasitic ciliate Ichthyophthirius multifiliis

The protective effect in rainbow trout (Oncorhynchus mykiss) of an experimental subunit vaccine targeting antigens in the parasite Ichthyophthirius multifiliis has been evaluated and compared to effects elicited by a classical parasite homogenate vaccine. Three recombinant parasite proteins (two produced in E. coli and one in insect cells) were combined and injected i.p., and subsequently, protection and antibody responses were analysed. Both the experimental and the benchmark vaccine induced partial but significant protection against I. multifiliis when compared to control fish. Specific antibody responses of vaccinated trout (subunit vaccine) were raised against one neurohypophysial n‐terminal domain protein #10 of three recombinant proteins, whereas the benchmark vaccine group showed specific antibody production against all three recombinant proteins. The immunogenic parasite protein #10 may be a potential vaccine candidate supplementing the protective I‐antigen in future vaccine trials.     

鳗弧菌口服微胶囊疫苗的制备及其对鲈鱼的免疫效果

以分离自患病鲈鱼(Lateolabrax     

Growth and performance of Atlantic salmon, Salmo salar L., following administration of a rhabdovirus DNA vaccine alone or concurrently with an oil-adjuvanted, polyvalent vaccine

This research demonstrates for the first time an absence of growth-related side effects in Atlantic salmon, Salmo salar L., following the injection of a DNA vaccine alone or concurrently with a commercially available, polyvalent, oil-adjuvanted vaccine. Using weight and specific growth rate measurements, individually tagged Atlantic salmon were monitored for 2028 degree days (dd) post-vaccination. During this time, DNA-vaccinated fish did not differ in weight, length, condition factor or specific growth rate compared to unvaccinated control fish. While differences in weight were observed between unvaccinated control and concurrently vaccinated fish, there were no significant differences in weight, length, condition factor or specific growth rate between concurrently vaccinated fish and adjuvant-vaccinated fish, suggesting that only adjuvant vaccination affected growth. To further determine if concurrent injection of a DNA vaccine and a polyvalent, oil-adjuvanted vaccine had a physiological impact on the Atlantic salmon, swimming performance tests were performed at 106 dd post-vaccination with U _crit,1, U _crit,2, the U _crit recovery ratio (RR) and the normalized RR being similar to values obtained from unvaccinated control fish. In summary, this study shows that concurrent injection of a DNA vaccine and a polyvalent, oil-adjuvanted vaccine does not negatively influence the growth or swimming performance of Atlantic salmon compared to adjuvant vaccination alone.     

Efficacy of a Live‐attenuated Edwardsiella ictaluri Oral Vaccine in Channel and Hybrid Catfish

This study evaluated the efficacy of an oral live‐attenuated Edwardsiella ictaluri vaccine against enteric septicemia of catfish (ESC) in channel and hybrid catfish. The vaccine was delivered one time orally by feeding fish a diet coated with an attenuated E. ictaluri isolate at four doses to deliver between 4 × 10⁶ to 3.2 × 10⁷ viable vaccine cells/g wet feed. Thirty‐five days postvaccination, control and vaccinated fish were challenged with virulent E. ictaluri and mortality was examined for 30 d postchallenge. Mortality of nonvaccinated hybrids (85%) and nonvaccinated channel catfish (73%) was similar but significantly greater than all groups of vaccinated fish. In channel catfish, a trend toward increasing mortality with decreasing dose was observed. Mortality of channel catfish vaccinated with the lowest dose (26.6%) was significantly higher than fish vaccinated with the highest dose (14.1%) but similar to fish vaccinated at the intermediate doses (17.5 and 19.4%). In contrast, mortality of four doses of vaccinated hybrid catfish was similar and ranged between 10.4 and 14.0%. The data demonstrate that the attenuated E. ictaluri vaccine at all four doses tested is effective at reducing ESC‐related mortalities in hybrid and channel catfish.     

Live vaccine trials against nocardiosis in yellowtail Seriola quinqueradiata

In an attempt to develop a vaccine against Nocardia seriolae, related species of live bacteria N. soli, N. fluminea, and N. uniformis were injected into yellowtail Seriola quinqueradiata. In addition, fish were challenged with a low virulence strain of N. seriolae to model the concept of use of a live vaccine. The fish injected with live N. soli and N. fluminea cells showed slight resistance against an artificial challenge with N. seriolae. On the other hand, the fish that survived the N. seriolae infection showed complete resistance to the N. seriolae challenge. These results suggest that protective immune responses against N. seriolae are induced in yellowtails.     

Randomized clinical field trial of a bacterial kidney disease vaccine in Atlantic salmon,Salmo salar L.

A randomized, blinded clinical trial was performed to assess the relative effectiveness of five commercial and one experimental vaccine in a population of farmed fish experiencing a bacterial kidney disease (BKD) outbreak that occurred in one study cage that was part of a larger clinical field trial. A total of 6000 uniquely identified Atlantic salmon S1 presmolts were randomly assigned to vaccine groups in the hatchery and transferred to a commercial marine aquaculture site. Repeated sampling events to evaluate growth, inherent physical conditions and health status were carried out over the entire production cycle. During the second summer at sea, the study cage developed an outbreak of BKD that lasted approximately 240 days. The effectiveness of the selected vaccines was evaluated using survival analysis methods. The sole vaccine group offering protection for BKD was found to significantly decrease the hazard of dying (hazard ratio, HR = 0.68, P = 0.018) during the outbreak, compared to the industry standard, vaccine group. Additionally, during the outbreak, fish with a shortened operculum had a significantly decreased hazard (HR = 0.38, P = 0.033) compared to those fish with a normal operculum, while fish with jaw deformities had a significantly increased hazard (HR = 2.55, P = 0.001) compared to fish with normal jaw status.     

H5亚型禽流感灭活油乳剂疫苗对鸭的免疫试验

H5亚型禽流感(AI)油乳剂灭活疫苗接种成年鸭和幼鸭后,用ELISA法检测抗体消长规律,结果表明,AIVH5亚型灭活油乳剂疫苗两次接种可以有效地预防成年鸭,而一剂H5亚型AIV灭活油乳剂疫苗接种幼鸭后的免疫应答反应不好。     

口服嗜水气单胞菌生物被膜疫苗的动物免疫试验

将热灭活的嗜水气单胞菌(Aeromonashydrophila)生物被膜(biofilm,BF)菌苗和浮游(freecell,FC)菌苗口服免疫小鼠和剑尾鱼,通过测定抗体效价、相对保护率、小鼠的淋巴细胞转化和肠道sIgA浓度,评价免疫效果。免疫20d后,BF菌苗组50尾剑尾鱼的相对保护率为68%;FC菌苗组为42%。BF菌苗组12只小鼠的相对保护率为70%;FC菌苗组为50%;对照组为17%。BF菌苗组小鼠外周血淋巴细胞转化率是7.28、FC菌苗组为3.87、对照组为2.36。BF菌苗组小鼠肠道sIgA浓度是1.22μg/mL;FC菌苗组为0.73μg/mL;对照组为0.465μg/mL。免疫30d后,小鼠的血清凝集抗体达到最高,BF组抗体达128:1,FC组为32:1,对照组为2:1。各组间差异显著(P<0.01)。结果表明,BF菌苗较FC菌苗能更有效地刺激机体的免疫系统,尤其是肠道淋巴组织的免疫应答,对剑尾鱼和小鼠具有较好的保护力。